Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Guilherme Oliveira

Cardiovascular Disease Tampa, FL Medical Doctor

NPI 1699879098 CMS profile 258235

2 Tampa General Cir, Tampa, FL 33606

Open in the dashboard

General payments

$79,052

121 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,995 paid to institutions, not to them · program year 2019

Through program year 2025, Guilherme Oliveira of Tampa, FL is reported in the CMS Open Payments database as having received $79,052 across 121 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,995 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $247 8
2024 General $1,653 9
2023 General $225 6
2022 General $442 6
2021 General $7,170 7
2020 General $7,361 10
2019 General $61,953 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Guilherme Oliveira
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Guilherme Oliveira were reported at $247. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Guilherme Oliveira Cardiovascular Disease median Middle half National median
2019 $61,953 $450 $127–$1,392 $163
2020 $7,361 $242 $77–$751 $114
2021 $7,170 $335 $101–$1,037 $132
2022 $442 $395 $121–$1,211 $149
2023 $225 $443 $136–$1,283 $160
2024 $1,653 $450 $136–$1,323 $164
2025 $247 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Relypsa, Inc. $25,927 17 payments
  2. Pfizer Inc. $23,358 24 payments
  3. Novartis Pharmaceuticals Corporation $12,325 12 payments
  4. Alnylam Pharmaceuticals Inc. $6,266 10 payments
  5. Abbott Laboratories $5,115 23 payments
  6. E.R. Squibb & Sons, L.L.C. $2,700 2 payments
  7. Abiomed $2,690 13 payments
  8. Amgen Inc. $257 6 payments
  9. Daxor Corporation $128 1 payment
  10. Zimmer Biomet Holdings, Inc. $84 1 payment
  11. Other $203 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $46,885 17 payments
  2. Consulting Fee $17,811 6 payments
  3. Travel and Lodging $8,134 22 payments
  4. Food and Beverage $4,472 75 payments
  5. Honoraria $1,750 1 payment
Products named General payments · program years 2019–2025
  1. Veltassa $25,927 17 payments
  2. VYNDAQEL $23,349 23 payments
  3. ENTRESTO $12,304 11 payments
  4. ONPATTRO $6,266 10 payments
  5. CardioMEMS HF System $3,276 10 payments
  6. Impella $2,655 12 payments
  7. CARDIOMEMS $1,331 5 payments
  8. HeartMate 3 Left Ventricular Assist Device $168 1 payment
  9. Repatha $161 5 payments
  10. Mitra Clip system $146 1 payment
  11. Other $732 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

2,632

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$2,299,296

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

57.2%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 22 $458,506
Entresto Sacubitril/Valsartan Brand 327 $421,705
Farxiga Dapagliflozin Propanediol Brand 326 $390,979
Vyndaqel Tafamidis Meglumine Brand 16 $335,542
Repatha Sureclick Evolocumab Brand 106 $137,366
Eliquis Apixaban Brand 89 $122,798
Mounjaro Tirzepatide Brand 76 $92,995
Ozempic Semaglutide Brand 66 $89,853
Repatha Pushtronex Evolocumab Brand 70 $51,538
Jardiance Empagliflozin Brand 25 $40,724

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$44,943

Medicare's payments for the services billed

Medicare patients

268

Average age 70

Services billed

635

95 women, 173 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 72%
Chronic kidney disease 62%
Diabetes 54%
Atrial fibrillation 51%
Arthritis 51%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $18
$18 24 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

121 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record